In my September 15, 2019 HEICO Corporation (HEI and HEI-a) post, I disclosed the purchase of 300 shares @ ~$99/share in one of the 'Side' accounts in the FFJ Portfolio. Subsequently, I have increased my exposure to 400 shares in a 'Core' account and 400 shares in a 'Side' account. What initially peaked my interest [...]
Income seeking investors who prioritize dividend metrics in their investment decision making process should consider CME Group (CME) as a potential investment. While it has consistently increased its dividend payout for 13 consecutive years, the real 'kicker' is the variable component. CME's dividend policy targets a regular quarterly dividend of between 50% - 60% of [...]
In my December 8 guest post at Dividend Power, I outline how Thermo Fisher Scientific consistently creates shareholder value and why I think this is an opportune time to acquire shares despite its valuation is not as attractive as in late October/early November. Thermo Fisher's share price can be volatile. Just before Christmas 2021, for [...]
In late October/early November, identifying attractively valued wonderful companies was reasonably easy. Irrational exuberance, however, returned part way through November. This has me thinking that many investors are making emotional investment decisions. This is a terrible way to invest since our emotions have a tremendous influence over our expectations. When we neglect to look at [...]
The phrase 'exit stage right' is a playwright's way of giving clear directions for a character to leave the stage. This is exactly what I have done with my Abbvie (ABBV) exposure. In my December 2 Why I Am Not Increasing My AbbVie Exposure post, I explain my decision not to add to my ABBV [...]
Alimentation Couche-Tard (ATD.to) is arguably the best operator in the highly fragmented convenience store industry. Despite being a wonderful company, however, shares are currently fairly valued. I am not, therefore, currently adding to my exposure. I think we are once again experiencing a period of irrational exuberance. In late October/early November, it was easy to [...]
I last reviewed Abbvie (ABBV) in my November 12, 2022 post at which time I expressed my relief that ABBV was deleveraging. Now, however, ABBV's debt will increase because of its recently announced ImmunoGen (IMGN) acquisition. I am, therefore, not increasing my Abbvie exposure for reasons presented herein. In my previous post, I also commented [...]
Following the November 20 market close, A released its Q4 and FY2023 results and Q1 and FY2024 guidance. Despite the challenging market conditions, Agilent forecasts strong cash flow in FY2024. When I reviewed Agilent Technologies (A) in my August 16 post, it had just released its Q3 and YTD2023 results and revised FY2023 guidance. At [...]
Zoom Video Communications (ZM) raises guidance for the 3rd time in FY24. With the release of Q3 and YTD2024 results on November 20 and revised guidance, I revisit ZM and disclose the purchase of additional shares in one of the 'Core' accounts within the FFJ Portfolio. NOTE: Do not confuse ZM with ZoomInfo Technologies Inc. [...]
When I last reviewed Copart (CPRT) in this September 16, 2023 post, it had just released its FY2023 results. On October 10, Copart announced that it is transforming the auction world with the acquisition of a majority interest in Purple Wave, an online heavy equipment auction company. Now that we have CPRT's Q1 2024 financial [...]